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Medullary thyroid carcinoma is a rare malignancy that arises from calcitonin-producing C-cells and frequently metastasizes to
lymph nodes in the neck. Distant metastases may involve bone, lung, and liver. The infrequent number of cases limits the clinical
nature and ability to optimize diagnostic tools. Here, we present a case of a micronodular radiographic pattern in metastatic
medullary thyroid cancer in order to enhance awareness of the disease process. A case discussion and relevant review of the
literature are provided.
1.Introduction
Medullary thyroid carcinoma (MTC) is an uncommon
primary thyroid tumor that accounts for as much as 5%–
10% of all thyroid malignancies [1–5] and as much as 13%
of all thyroid cancer-related deaths [4, 5]. MTC lesions can
metastasize to regional lymph nodes but may also spread
hematogenously and aﬀect the liver, bone, and lungs [6].
Metastases to the lung generally exhibit a macronodular
appearance [7, 8], but other pulmonary patterns have been
described in the literature. The diverse radiographic mani-
festations of pulmonary MTC metastases pose a diagnostic
challenge for clinicians. In this paper, we present the case of
a 40-year-old man diagnosed with MTC and micronodular
lung metastases.
2.CaseReport
A 40-year-old man was admitted to the hospital with
complaints of diarrhea and an unintentional weight loss
of 5kg over the past 6 months. The patient was in good
condition and had a physical examination that was normal,
with the exception of thyroid swelling, and an enlarged
cervical node that was revealed during examination of the
neck. The hemogram, urea, creatinine, liver function tests,
and urinalysis were all normal.
Tests of thyroid function indicated a thyroid-stimulating
hormone level of 1.05uIU/mL (reference range: 0.4–
4.0uIU/mL), thyroglobulin of 16.0ng/mL (reference range:
5–50ng/mL), thyroglobulin antibody of 8.0U/mL (reference
range: 1–10U/mL), free tyrosine of 1.6ng/dL (reference
range: 0.8–1.9ng/dL), triiodothyronine 118ng/dL (reference
range: 60–181ng/dL), antiperoxidase of 12.4U/mL (refer-
ence range: under 15U/mL), and sedimentation rate of
6mm 3/hour (reference range: 0–15mm3/hour).
Thyroid ultrasonography showed a hypoechogenic 3cm
mass in the right lobe of the thyroid. Scintigraphy revealed
an enlarged right lobe that showed no concentration of
radiotracer. A ﬁne-needle aspiration from the thyroid mass
revealed that cells had an outlining glandular arrangement
and were consistent with malignant epithelial tumor cells.
The absence of family history of MTC indicated that
the carcinoma present was of a sporadic nature. Pheochro-
mocytoma was excluded based on a normal abdominal2 Case Reports in Medicine
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Figure 1: Chest radiographs in anteroposterior (a) and lateral (b)
incidences showing inﬁltration by small nodules disseminated in
both lungs.
computed tomography (CT) scan, normal plasma cat-
echolamine levels, and excretion of metanephrine and
normetanephrine in a urine sample collected after 24 hours.
The serum preoperative calcitonin level was signiﬁcantly
elevated at 22.450pg/mL (reference range: 0–42pg/mL),
and carcinoembryogenic antigen (CEA) level was 574g/mL
(reference range 0–3ng/mL). The patient underwent a total
thyroidectomy with bilateral neck dissection. Histopatho-
logical examination revealed a thyroid medullary carcinoma
with metastasis to cervical lymph nodes in levels II, III, and
IV. As a result, surgical staging was considered IVb (T2 N1b
M0). Immunohistochemical analyses detected expression
of antithyroglobulin, anticalcitonin, and antichromogranin
A. Postoperatively, calcitonin levels decreased to 382pg/ml
and CEA levels decreased to 309ng/mL. An additional
thyroid ultrasonography was performed, and a persistent
hypoechogenic 2.1cm mass was detected in the right lobe of
the thyroid. Abdominal and thorax CT scans were normal.
One month after surgery, the patient underwent 25 ses-
sionsofradiotherapyofthecervicalanduppermediastinum.
Within 6 months from the start of the therapy, the levels
of CEA and calcitonin slowly decreased to 243ng/mL and
214pg/mL, respectively. The patient failed to attend the
control visits.
The patient went to the hospital two years after the treat-
mentwithcomplaintsofwastingsyndromeandchronicdiar-
rhea (10episodes/day). The laboratory tests showed calci-
tonin levels of 32.137pg/mL and CEA levels of 658.8ng/mL.
A plain chest radiograph showed a diﬀuse micronodular
pattern in both lung ﬁelds (Figure 1). A bronchoscopy
performed was normal and the bronchoalveolar lavage and
culture for mycobacteria and fungi were negative. There
was also an absence of neoplastic cells. A CT of the thorax
revealed multiple pulmonary nodules that were suggestive of
metastases (Figure 2). When an abdominal ultrasound was
performed, metastatic disease in the liver was detected that
consisted of two hyperechogenic nodules, a 10mm nodule in
segment VII and a 9 mm nodule in segment VIII.
The patient was discharged one month later and was
given octreotide (Sandostatin LAR), Puran T4, CaCO3, and
vitamin D3 to take for treatment. The decision to start
octreotide was based on positive expression of somatostatin
receptors detected on an octreoscan. Three months after
discharge, the patient is undergoing ambulatory follow-up
and has a satisfactory clinical response with weight gain, a
reduced incidence of diarrhea, and normal laboratory tests
resulting in a signiﬁcant improvement in the patient’s overall
quality of life.
3. Discussion
Medullary thyroid carcinoma arises from the parafollicular
cells or C-cells of the thyroid gland, which produce cal-
citonin and are neuroendocrine in origin [6]. In MTCs,
the calcitonin levels are critical for both diagnosis and
postoperative surveillance [6]. MTC can occur as a non-
inherited, sporadic disease that typically presents in the
fourth decade of life. It can also be transmitted genetically
in an autosomal dominant inheritance pattern that is
associated with either familial medullary carcinoma of the
thyroid (FMTC), multiple endocrine neoplasia (MEN)-IIA
(MTC, pheochromocytoma, and hyperparathyroidism), or
MEN-IIB (MTC, pheochromocytoma, mucosal neuroma,
and marfanoid habitus). The sporadic variant is typically
unilateral and corresponds to approximately 75% of all MTC
cases [6].
At the initial diagnosis, the sporadic variant of MTC
often presents with distant metastasis involving cervical
lymph nodes, lungs, liver, and bones and is the main cause
of MTC-related death [4, 9]. Metastases to the brain and skin
are not observed as frequently. Distant metastases are usually
diﬀuse and abundant and generally aﬀect multiple organs
[1]. Despite a high rate of metastasis to the lymph node,
the 5-year and 10-year survival rates for MTC are between
78%–91%and61%–75%,respectively[6,10].Ingeneral,the
overall survival rate of patients with MTC is intermediate
to that of patients with diﬀerentiated thyroid carcinoma
(papillary and follicular) and anaplastic carcinoma [11, 12].
Patients with the sporadic form of MTC and who have
systemic symptoms generally have broad metastatic disease
[11]. Of those patients, 33.3% die within 5 years [11]. Our
patient presented the sporadic form of the disease.
Prognostic factors that are relevant to the outcome of
patients diagnosed with MTC include the age at diagnosis,
male gender, the initial extent of the disease (including
lymphnodeanddistantmetastases),tumorsize,extrathyroid
invasion, vascular invasion, calcitonin immunoreactivity,
and amyloid staining in tumor tissue [1, 11, 13, 14]. A
total thyroidectomy with meticulous triple compartment
nodal dissection correlates with the highest survival rate
for patients. Therefore, aggressive methods to detect and
characterize tumor behavior as early as possible are the best
approaches for increasing patient survival rates [7, 15]. The
beneﬁts of adjuvant external beam irradiation to the neck
(EBRT) have been poorly evaluated, remain controversial,
and are not predicted to provide normalization of serum
levels of calcitonin [16]. However, in high risk patients
with microscopic residual disease, extraglandular invasion,
orlymphnodeinvolvement,thelocal/regionrelapse-freerate
was found to be 86% after 10 years following treatmentCase Reports in Medicine 3
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Figure 2: High-resolution CT scans at four diﬀerent levels showing small nodules distributed randomly through the lungs. Note that the
nodules are larger in the lung bases (d).
with postoperative EBRT versus 52% for patients who did
not receive EBRT. EBRT could also be applied to patients
with macroscopic disease after incomplete surgery for local
disease control [16].
Elevated basal calcitonin concentrations are found in
MTC, C cell hyperplasia, and in rare subjects without any
C cell abnormalities [1]. The prognostic value of calcitonin
immunostaining has been studied in primary [4, 17, 18]
and metastatic tumors [4, 16]. These studies concluded
that calcitonin-poor primary tumors were associated with
lower survival rates [4, 17, 18]. The same was also true for
calcitonin-poor metastases [4, 17], which had an aggressive
clinical course and poor prognosis [4, 19]. In patients
with MTC, the calcitonin levels become undetectable after
extensive surgery in most patients without neck lymph
node metastases but remain elevated in two thirds of the
patients with neck lymph node involvement [1, 20–22].
An elevated calcitonin level indicates persistent disease and
requires multiple imaging procedures [19, 23, 24]. CEA
is produced by neoplastic C cells. Measurement of serum
CEA concentration is useful during follow-up, since high
concentrations or rapidly increasing concentrations indicate
disease progression [1, 25].
Medullary carcinomas of the thyroid commonly exhibit
a macronodular pattern, also known as a “cannonball”
appearance, with clear-cut margins [4, 7]. Although the
pulmonary micronodular patterns appear more commonly
in metastatic papillary thyroid cancer [7, 8], the case
presented here indicates that they can also occur in MTC.
Unfortunately, a micronodular pulmonary pattern can also
be easily mistaken for granulomatous diseases, such as
tuberculosis, histoplasmosis, or sarcoidosis, which further
complicate the diagnosis [7]. A diagnosis is based on the
patient’s history, clinical assessment, tumor markers, and
histopathological examination of the primary or metastatic
lesion. In addition to an MTC diagnosis, an accurate
determination of the extent of disease is important for the
initial treatment [8, 26]. Reticulonodular perihilar lesions
[4, 7, 27] and calciﬁed pulmonary metastases [2, 4, 7, 28]
have also been reported in the literature, and it is known that
theincidenceofcalciﬁedmetastasisattheinitialpresentation
is high in patients with MTC [8, 26, 29]. In a review
of the literature, very few cases have been reported to
have micronodular patterns [7, 27]. Metastatic disease is
an important cause of micronodular pulmonary patterns.
Since metastases are detected after the primary lesion is
identiﬁed, a presumptive diagnosis of metastasis from the
known primary lesion is an accurate diagnosis.
It is also important to consider that there is currently
no single, sensitive diagnostic imaging modality for the
detection of all metastases present in patients with MTC.
Therefore in many cases, several imaging modalities are
employed, such as ultrasonography, computerized tomogra-
phy, scintigraphy using pentavalent technetium-99m dimer-
captosuccinic acid, thallium-201 chloride, and indium-111
pentetreotide, as well as ﬂuorine-18 ﬂuorodeoxyglucose4 Case Reports in Medicine
positron emission tomography (18F-FDG PET/CT). The
consecutive administration of these techniques has been
applied to patients with elevated calcitonin levels until
tumors present were detected [30]. Thallium 201-chloride
single-photon emission CT has also been shown to detect
metastatic diﬀerentiated thyroid carcinoma foci as small as
1cm in the neck, 1.5cm in the lung, and disseminated
micronodular pulmonary metastases, especially in patients
whose scans were negative following administration of 131I
[7, 31]. A short review by Conry et al. [32] showed that nei-
ther 18F-FDG PET/CT, nor the novel PET somatostatin ana-
logue, 68Ga-DOTATATE PET/CT, can fully map the extent
of disease in patients with recurrent MTC, although 18F-
FDG PET/CT may identify more lesions. 68Ga-DOTATATE
PET/CT also represents a useful, complementary imaging
tool for the detection of the extent of disease and has the
potential to identify patients that may qualify for targeted
radionuclide somatostatin analogue therapy.
Finally, no eﬀective therapy is currently available for the
managementofpatients withMTC.AccordingtoLeboulleux
et al. [1], treatment with radioactive iodine is ineﬀective
since C cells do not take up radioiodine. Alternatively, the
eﬃcacy of pretargeted radioimmunotherapy (pRAIT) that
uses bispeciﬁc monoclonal antibodies in combination with
an iodine-131- (131I-) labeled bivalent hapten was evaluated
by Chatal et al. [33]. pRAIT was found to provide long-term
disease stabilization for patients with CEA and a signiﬁcantly
longer survival for high-risk patients that were characterized
with short serum calcitonin doubling times (Ct DTs) of less
than 2 years compared to high-risk patients that remained
untreated. Ct DT and bone-marrow involvement also appear
to be prognostic indicators in MTC patients who undergo
pRAIT.
4. Conclusion
MTC that exhibits a micronodular pulmonary pattern
represents a relatively rare presentation of metastatic MTC,
since most pulmonary metastases exhibit macronodular
patterns. It is imperative to use all available sources to
accurately diagnose and cure this type of aggressive tumor
and appropriately exclude inﬂammatory causes. We have
presented a case of medullary thyroid carcinoma with
micronodular pulmonary metastases to enhance awareness
of this uncommon presentation of a rare and aggressive
disease.
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